Abstract
CA19-9 is a biomarker often used in pancreatic cancer diagnosis; it measures serum CA19-9 levels in the blood which corresponds to cancer status and even staging. It is used clinically but not as a screening biomarker as it doesn’t have the specificity needed to make it cost-effective in a screening programme. It can be used before and after treatment as it can help in choosing a treatment plan. It is used to see if this treatment is working, so it works as a predictive and prognostic biomarker as well. It’s recently been used alongside tumour marker genes to improve its sensitivity and specificity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Biomedical Research & Environmental Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
